JP2023519562A5 - - Google Patents
Info
- Publication number
- JP2023519562A5 JP2023519562A5 JP2022556158A JP2022556158A JP2023519562A5 JP 2023519562 A5 JP2023519562 A5 JP 2023519562A5 JP 2022556158 A JP2022556158 A JP 2022556158A JP 2022556158 A JP2022556158 A JP 2022556158A JP 2023519562 A5 JP2023519562 A5 JP 2023519562A5
- Authority
- JP
- Japan
- Prior art keywords
- cov
- sars
- protein
- amino acid
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20167405.8 | 2020-03-31 | ||
| EP20167405 | 2020-03-31 | ||
| PCT/EP2021/058513 WO2021198376A1 (en) | 2020-03-31 | 2021-03-31 | Novel salmonella-based coronavirus vaccine |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026077196A Division JP2026131609A (ja) | 2020-03-31 | 2026-05-01 | サルモネラに基づく新規コロナウイルスワクチン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023519562A JP2023519562A (ja) | 2023-05-11 |
| JP2023519562A5 true JP2023519562A5 (enExample) | 2024-04-08 |
Family
ID=70110247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022556158A Pending JP2023519562A (ja) | 2020-03-31 | 2021-03-31 | サルモネラに基づく新規コロナウイルスワクチン |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230137174A1 (enExample) |
| EP (1) | EP4126022A1 (enExample) |
| JP (1) | JP2023519562A (enExample) |
| KR (1) | KR20220161444A (enExample) |
| CN (1) | CN115715198A (enExample) |
| AU (1) | AU2021250442A1 (enExample) |
| CA (1) | CA3170674A1 (enExample) |
| WO (1) | WO2021198376A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY39378A (es) * | 2020-08-14 | 2022-01-31 | Univ Wuerzburg J Maximilians | Vacuna de salmonella para el tratamiento de coronavirus |
| CN114517205A (zh) * | 2020-11-20 | 2022-05-20 | 北京震旦鼎泰生物科技有限公司 | 融合基因及一种重组新型冠状病毒高效免疫鼎分子dna疫苗及其构建方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060240515A1 (en) * | 2003-07-21 | 2006-10-26 | Dimitrov Dimiter S | Soluble fragments of the SARS-CoV spike glycoprotein |
| EP1654364A4 (en) * | 2003-08-13 | 2008-02-13 | Novartis Vaccines & Diagnostic | CURRENT HOST CELL RELEASE COMPRISING POLYNUCLEOTIDES ENCODING IMMUNOGENS |
| CN1327900C (zh) * | 2005-03-30 | 2007-07-25 | 武汉大学 | 一种染色体上携带病毒基因的减毒伤寒杆菌疫苗及制备方法 |
| BR112014015706A2 (pt) | 2011-12-22 | 2020-10-27 | Vaximm Ag | método para o cultivo de uma estirpe mutante atenuada de salmonella typhi, estirpe mutante atenuada de salmonella typhi e salmonella typhi ty21a |
| WO2018213242A1 (en) * | 2017-05-15 | 2018-11-22 | University Of Maryland, Baltimore | Live salmonella typhi vectors engineered to express heterologous outer membrane protein antigens and methods of use thereof |
| WO2020237246A1 (en) * | 2019-05-23 | 2020-11-26 | University Of Maryland, Baltimore | Live attenuated non-transmissible vaccines |
| US10973908B1 (en) * | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
-
2021
- 2021-03-31 CA CA3170674A patent/CA3170674A1/en active Pending
- 2021-03-31 JP JP2022556158A patent/JP2023519562A/ja active Pending
- 2021-03-31 WO PCT/EP2021/058513 patent/WO2021198376A1/en not_active Ceased
- 2021-03-31 US US17/907,619 patent/US20230137174A1/en active Pending
- 2021-03-31 CN CN202180024934.7A patent/CN115715198A/zh active Pending
- 2021-03-31 AU AU2021250442A patent/AU2021250442A1/en active Pending
- 2021-03-31 KR KR1020227037910A patent/KR20220161444A/ko active Pending
- 2021-03-31 EP EP21714916.0A patent/EP4126022A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010500399A5 (enExample) | ||
| JP2016539946A5 (enExample) | ||
| JP2020023567A5 (enExample) | ||
| CN104395336B (zh) | 以计算方式优化的h5n1和h1n1流感病毒的广泛反应性抗原 | |
| JP2024503265A5 (enExample) | ||
| JP2019526580A5 (enExample) | ||
| ES2431963T3 (es) | Partícula viral adyuvante | |
| JP2008529558A5 (enExample) | ||
| JP2024516309A5 (enExample) | ||
| BR112013032381B1 (pt) | composições à base de levedura e métodos para o tratamento ou prevenção de infecção pelo vírus da hepatite delta | |
| JP2017515508A5 (enExample) | ||
| JP2014524480A5 (enExample) | ||
| JP2014508734A5 (enExample) | ||
| CN107188934A (zh) | 以计算方式优化的人和禽h5n1流感的广泛反应性抗原 | |
| US20170165321A1 (en) | Method for reducing and/or delaying pathological effects of human immunodeficiency virus i (hiv) or for reducing the risk of developing acquired immunodeficiency syndrome (aids) | |
| JP2022500042A5 (enExample) | ||
| JP2017533211A5 (enExample) | ||
| ES2533345T3 (es) | Diferentes serotipos del virus de la estomatitis vesicular como vectores de expresión para regímenes de inmunización | |
| JP2020536925A5 (enExample) | ||
| BRPI0811692A2 (pt) | material com imunogenicidade | |
| Harfouch et al. | Therapeutic approaches for COVID 19: Challenges and successes | |
| JP2020536098A5 (enExample) | ||
| ES2991384T3 (es) | Composición farmacéutica, formulación farmacéutica combinada y kit de formulación combinada para la prevención o el tratamiento de la hepatitis B crónica, que comprende cada uno, como ingrediente activo, un agente antiviral oral y una vacuna terapéutica que incluye un lipopéptido y un adyuvante poli(I:C) | |
| JP7635208B2 (ja) | Ｂ型肝炎ウイルスワクチン | |
| CN110769843A (zh) | C5a受体激动剂肽的盐酸盐 |